Nuvectis Pharma, Inc. (NVCT) - Dilution Analysis

10-Q filing | 26.5M shares outstanding

10-Q filing | 25.6M shares outstanding

10-Q filing | 25.5M shares outstanding

10-Q filing | 23.6M shares outstanding

10-K filing | 19.5M shares outstanding

8-K filing: Nuvectis Pharma, Inc. completed a public offering of 3,105,000 shares of common stock at a price of $5.00 per share, resulting in net proceeds of approximately $14.4 million.

10-Q filing | 17.2M shares outstanding

10-Q filing | 16.9M shares outstanding

10-Q filing | 16.6M shares outstanding

10-K filing | 17.4M shares outstanding

10-Q filing | 16.1M shares outstanding

10-Q filing | 15.2M shares outstanding

10-Q filing | 14.7M shares outstanding

S-3 filing: This S-3 filing by Nuvectis Pharma, Inc. includes information about the potential offering of common stock, preferred stock, debt securities, and/or units consisting of any combination of common stock, preferred stock, warrants or debt securities with a total proposed amount of $150,000,000.

10-K filing | 14.6M shares outstanding

10-Q filing | 14.1M shares outstanding

S-1 filing: This prospectus relates to the offer and resale from time to time by the selling securityholders named in this prospectus of shares of common stock, par value $0.00001 per share of Nuvectis Pharma, Inc.

10-Q filing | 12.7M shares outstanding

8-K filing: Nuvectis Pharma, Inc. entered into definitive agreements for a private placement involving the issuance and sale of common stock, pre-funded warrants, and preferred investment options, resulting in gross proceeds of approximately $15.9 million. ($15.9M proceeds)

10-Q filing | 12.7M shares outstanding

8-K filing: Nuvectis Pharma, Inc. announced a 39-for-1 stock split effective February 3, 2022, and the sale of 3,200,000 shares of common stock at $5.00 per share in an underwritten offering. ($16.0M proceeds)

S-1/A filing: This is an S-1/A filing for Nuvectis Pharma, Inc. registering common stock and representative warrants.

S-1/A filing: This S-1/A filing relates to an offering of common stock and representative warrants, with the company planning to use the net proceeds to fund the Phase 1/2 development of NXP800, continue development and sponsored research, hire additional personnel, capital expenditures, costs of operating as a public company, and other general corporate purposes.

S-1/A filing: This S-1/A filing relates to an offering of common stock. The company intends to use the net proceeds of this offering to fund the Phase 1/2 development of NXP800, to continue development and sponsored research related to our current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.

S-1/A filing: This S-1/A filing from 2021-11-08 details an offering of 2,300,000 shares of common stock with an additional 345,000 shares available to underwriters, and discusses the company's plans for the net proceeds.

S-1/A filing: This S-1/A filing includes information on the offering of 2,300,000 shares of common stock. It also mentions that 11,817,794 shares of common stock to be outstanding after this offering (or 12,162,794 shares if the underwriters exercise their option to purchase additional shares in full).

S-1/A filing: This S-1/A filing relates to an offering of common stock.

S-1 filing: S-1 filing for an offering of common stock.